ID   KPCA_HUMAN              Reviewed;         672 AA.
AC   P17252; B5BU22; Q15137; Q32M72; Q96RE4;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   12-OCT-2022, entry version 242.
DE   RecName: Full=Protein kinase C alpha type;
DE            Short=PKC-A;
DE            Short=PKC-alpha;
DE            EC=2.7.11.13;
GN   Name=PRKCA; Synonyms=PKCA, PRKACA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-568.
RC   TISSUE=Blood;
RX   PubMed=2336401; DOI=10.1093/nar/18.8.2183;
RA   Finkenzeller G., Marme D., Hug H.;
RT   "Sequence of human protein kinase C alpha.";
RL   Nucleic Acids Res. 18:2183-2183(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568.
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-568.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-445.
RX   PubMed=1714454; DOI=10.1016/s0021-9258(18)98596-0;
RA   McSwine-Kennick R.L., McKeegan E.M., Johnson M.D., Morin M.J.;
RT   "Phorbol diester-induced alterations in the expression of protein kinase C
RT   isozymes and their mRNAs. Analysis in wild-type and phorbol diester-
RT   resistant HL-60 cell clones.";
RL   J. Biol. Chem. 266:15135-15143(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57.
RA   Haridasse V., Hackenbruck J., Glazer R.I.;
RT   "Homo sapiens protein kinase C alpha 5-flanking sequence.";
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PROTEIN SEQUENCE OF 2-19.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [9]
RP   FUNCTION IN APOPTOSIS, AND SUBCELLULAR LOCATION.
RX   PubMed=9738012; DOI=10.1074/jbc.273.39.25436;
RA   Ruvolo P.P., Deng X., Carr B.K., May W.S.;
RT   "A functional role for mitochondrial protein kinase Calpha in Bcl2
RT   phosphorylation and suppression of apoptosis.";
RL   J. Biol. Chem. 273:25436-25442(1998).
RN   [10]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=9830023; DOI=10.1074/jbc.273.49.32787;
RA   St-Denis A., Chano F., Tremblay P., St-Pierre Y., Descoteaux A.;
RT   "Protein kinase C-alpha modulates lipopolysaccharide-induced functions in a
RT   murine macrophage cell line.";
RL   J. Biol. Chem. 273:32787-32792(1998).
RN   [11]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=9873035; DOI=10.1074/jbc.274.2.939;
RA   Han Y., Meng T., Murray N.R., Fields A.P., Brasier A.R.;
RT   "Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha autoregulatory
RT   feedback loop in hepatocytes. A role for protein kinase calpha in post-
RT   transcriptional regulation of ikappabalpha resynthesis.";
RL   J. Biol. Chem. 274:939-947(1999).
RN   [12]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=9927633; DOI=10.1124/mol.55.2.396;
RA   Shen L., Dean N.M., Glazer R.I.;
RT   "Induction of p53-dependent, insulin-like growth factor-binding protein-3-
RT   mediated apoptosis in glioblastoma multiforme cells by a protein kinase
RT   Calpha antisense oligonucleotide.";
RL   Mol. Pharmacol. 55:396-402(1999).
RN   [13]
RP   FUNCTION IN CELL CYCLE PROGRESSION.
RX   PubMed=10848585; DOI=10.1128/mcb.20.13.4580-4590.2000;
RA   Besson A., Yong V.W.;
RT   "Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell cycle
RT   progression.";
RL   Mol. Cell. Biol. 20:4580-4590(2000).
RN   [14]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=11909826; DOI=10.1161/01.res.0000012503.30315.e8;
RA   Wang A., Nomura M., Patan S., Ware J.A.;
RT   "Inhibition of protein kinase Calpha prevents endothelial cell migration
RT   and vascular tube formation in vitro and myocardial neovascularization in
RT   vivo.";
RL   Circ. Res. 90:609-616(2002).
RN   [15]
RP   INTERACTION WITH ADAP1.
RX   PubMed=12893243; DOI=10.1016/s0006-291x(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms of
RT   protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [16]
RP   FUNCTION IN PLATELET AGGREGATION.
RX   PubMed=12724315; DOI=10.1074/jbc.m212407200;
RA   Tabuchi A., Yoshioka A., Higashi T., Shirakawa R., Nishioka H., Kita T.,
RA   Horiuchi H.;
RT   "Direct demonstration of involvement of protein kinase Calpha in the Ca2+-
RT   induced platelet aggregation.";
RL   J. Biol. Chem. 278:26374-26379(2003).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF TNNT2/CTNT.
RX   PubMed=12832403; DOI=10.1074/jbc.m306325200;
RA   Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J.;
RT   "Identification of a functionally critical protein kinase C phosphorylation
RT   residue of cardiac troponin T.";
RL   J. Biol. Chem. 278:35135-35144(2003).
RN   [18]
RP   FUNCTION IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF TRPC1.
RX   PubMed=15016832; DOI=10.1074/jbc.m313975200;
RA   Ahmmed G.U., Mehta D., Vogel S., Holinstat M., Paria B.C., Tiruppathi C.,
RA   Malik A.B.;
RT   "Protein kinase Calpha phosphorylates the TRPC1 channel and regulates
RT   store-operated Ca2+ entry in endothelial cells.";
RL   J. Biol. Chem. 279:20941-20949(2004).
RN   [20]
RP   INTERACTION WITH PICK1.
RX   PubMed=15247289; DOI=10.1074/jbc.m404499200;
RA   Dev K.K., Nakanishi S., Henley J.M.;
RT   "The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and
RT   GluR2 as interacting ligands.";
RL   J. Biol. Chem. 279:41393-41397(2004).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF CSPG4, AND INTERACTION WITH CSPG4.
RX   PubMed=15504744; DOI=10.1074/jbc.m411045200;
RA   Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J., Mustelin T.,
RA   Stallcup W.B.;
RT   "Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates
RT   polarized membrane distribution and cell motility.";
RL   J. Biol. Chem. 279:55262-55270(2004).
RN   [22]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [24]
RP   INTERACTION WITH TRIM41.
RX   PubMed=17893151; DOI=10.1074/jbc.m703320200;
RA   Chen D., Gould C., Garza R., Gao T., Hampton R.Y., Newton A.C.;
RT   "Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin
RT   ligase.";
RL   J. Biol. Chem. 282:33776-33787(2007).
RN   [25]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=18056764; DOI=10.1093/cvr/cvm085;
RA   Xu H., Czerwinski P., Hortmann M., Sohn H.Y., Foerstermann U., Li H.;
RT   "Protein kinase C alpha promotes angiogenic activity of human endothelial
RT   cells via induction of vascular endothelial growth factor.";
RL   Cardiovasc. Res. 78:349-355(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-638 AND SER-651, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [30]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.m808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-628, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND THR-638, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   FUNCTION IN PHOSPHORYLATION OF EIF4G1.
RX   PubMed=21576361; DOI=10.1128/mcb.05589-11;
RA   Dobrikov M., Dobrikova E., Shveygert M., Gromeier M.;
RT   "Phosphorylation of eukaryotic translation initiation factor 4G1 (eIF4G1)
RT   by protein kinase C{alpha} regulates eIF4G1 binding to Mnk1.";
RL   Mol. Cell. Biol. 31:2947-2959(2011).
RN   [36]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=12417014; DOI=10.1093/oxfordjournals.jbchem.a003272;
RA   Nakashima S.;
RT   "Protein kinase C alpha (PKC alpha): regulation and biological function.";
RL   J. Biochem. 132:669-675(2002).
RN   [37]
RP   REVIEW ON FUNCTION.
RX   PubMed=19969380; DOI=10.1016/j.tips.2009.10.006;
RA   Konopatskaya O., Poole A.W.;
RT   "Protein kinase Calpha: disease regulator and therapeutic target.";
RL   Trends Pharmacol. Sci. 31:8-14(2010).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [39]
RP   FUNCTION IN CELL MIGRATION, AND SUBCELLULAR LOCATION.
RX   PubMed=23990668; DOI=10.1093/jnci/djt224;
RA   Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P.,
RA   Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.;
RT   "Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in
RT   cancer cell migration.";
RL   J. Natl. Cancer Inst. 105:1402-1416(2013).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10 AND SER-226, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; THR-638 AND SER-657, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   INTERACTION WITH PARD3.
RX   PubMed=27925688; DOI=10.1002/humu.23153;
RA   Chen X., An Y., Gao Y., Guo L., Rui L., Xie H., Sun M., Lam Hung S.,
RA   Sheng X., Zou J., Bao Y., Guan H., Niu B., Li Z., Finnell R.H.,
RA   Gusella J.F., Wu B.L., Zhang T.;
RT   "Rare deleterious PARD3 variants in the aPKC-binding region are implicated
RT   in the pathogenesis of human cranial neural tube defects via disrupting
RT   apical tight junction formation.";
RL   Hum. Mutat. 38:378-389(2017).
RN   [43]
RP   FUNCTION.
RX   PubMed=28028151; DOI=10.1084/jem.20160068;
RA   Xu X., Han L., Zhao G., Xue S., Gao Y., Xiao J., Zhang S., Chen P.,
RA   Wu Z.Y., Ding J., Hu R., Wei B., Wang H.;
RT   "LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates
RT   experimental autoimmune encephalomyelitis.";
RL   J. Exp. Med. 214:209-226(2017).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 320-672 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=19827831; DOI=10.1021/jm901108b;
RA   Wagner J., von Matt P., Sedrani R., Albert R., Cooke N., Ehrhardt C.,
RA   Geiser M., Rummel G., Stark W., Strauss A., Cowan-Jacob S.W., Beerli C.,
RA   Weckbecker G., Evenou J.P., Zenke G., Cottens S.;
RT   "Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-
RT   yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein
RT   kinase C isotypes.";
RL   J. Med. Chem. 52:6193-6196(2009).
RN   [45]
RP   STRUCTURE BY NMR OF 88-169.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second phorbol esters/diacylglycerol binding
RT   domain of human protein kinase C alpha type.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [46]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-98; ASN-467 AND VAL-489.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)-
CC       dependent serine/threonine-protein kinase that is involved in positive
CC       and negative regulation of cell proliferation, apoptosis,
CC       differentiation, migration and adhesion, tumorigenesis, cardiac
CC       hypertrophy, angiogenesis, platelet function and inflammation, by
CC       directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT,
CC       or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP.
CC       Involved in cell proliferation and cell growth arrest by positive and
CC       negative regulation of the cell cycle. Can promote cell growth by
CC       phosphorylating and activating RAF1, which mediates the activation of
CC       the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which
CC       facilitates active cyclin-dependent kinase (CDK) complex formation in
CC       glioma cells. In intestinal cells stimulated by the phorbol ester PMA,
CC       can trigger a cell cycle arrest program which is associated with the
CC       accumulation of the hyper-phosphorylated growth-suppressive form of RB1
CC       and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-
CC       apoptotic function in glioma cells and protects them from apoptosis by
CC       suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia
CC       cells mediates anti-apoptotic action by phosphorylating BCL2. During
CC       macrophage differentiation induced by macrophage colony-stimulating
CC       factor (CSF1), is translocated to the nucleus and is associated with
CC       macrophage development. After wounding, translocates from focal
CC       contacts to lamellipodia and participates in the modulation of
CC       desmosomal adhesion. Plays a role in cell motility by phosphorylating
CC       CSPG4, which induces association of CSPG4 with extensive lamellipodia
CC       at the cell periphery and polarization of the cell accompanied by
CC       increases in cell motility. During chemokine-induced CD4(+) T cell
CC       migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting
CC       in its dissociation from LRCH1 and the activation of GTPase CDC42
CC       (PubMed:28028151). Is highly expressed in a number of cancer cells
CC       where it can act as a tumor promoter and is implicated in malignant
CC       phenotypes of several tumors such as gliomas and breast cancers.
CC       Negatively regulates myocardial contractility and positively regulates
CC       angiogenesis, platelet aggregation and thrombus formation in arteries.
CC       Mediates hypertrophic growth of neonatal cardiomyocytes, in part
CC       through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA
CC       treatment, is required to induce cardiomyocyte hypertrophy up to heart
CC       failure and death, by increasing protein synthesis, protein-DNA ratio
CC       and cell surface area. Regulates cardiomyocyte function by
CC       phosphorylating cardiac troponin T (TNNT2/CTNT), which induces
CC       significant reduction in actomyosin ATPase activity, myofilament
CC       calcium sensitivity and myocardial contractility. In angiogenesis, is
CC       required for full endothelial cell migration, adhesion to vitronectin
CC       (VTN), and vascular endothelial growth factor A (VEGFA)-dependent
CC       regulation of kinase activation and vascular tube formation. Involved
CC       in the stabilization of VEGFA mRNA at post-transcriptional level and
CC       mediates VEGFA-induced cell proliferation. In the regulation of
CC       calcium-induced platelet aggregation, mediates signals from the
CC       CD36/GP4 receptor for granule release, and activates the integrin
CC       heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion.
CC       During response to lipopolysaccharides (LPS), may regulate selective
CC       LPS-induced macrophage functions involved in host defense and
CC       inflammation. But in some inflammatory responses, may negatively
CC       regulate NF-kappa-B-induced genes, through IL1A-dependent induction of
CC       NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-
CC       tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which
CC       modulates EIF4G1 binding to MKNK1 and may be involved in the regulation
CC       of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of
CC       KIT activity. Phosphorylates ATF2 which promotes cooperation between
CC       ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser-
CC       52' facilitating its ubiquitination and proteosomal degradation (By
CC       similarity). {ECO:0000250|UniProtKB:P20444,
CC       ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826,
CC       ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403,
CC       ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744,
CC       ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764,
CC       ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361,
CC       ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:28028151,
CC       ECO:0000269|PubMed:9738012, ECO:0000269|PubMed:9830023,
CC       ECO:0000269|PubMed:9873035, ECO:0000269|PubMed:9927633}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.13;
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00041};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000250|UniProtKB:P05696};
CC   -!- ACTIVITY REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB and
CC       PRKCG) are activated by calcium and diacylglycerol (DAG) in the
CC       presence of phosphatidylserine. Three specific sites; Thr-497
CC       (activation loop of the kinase domain), Thr-638 (turn motif) and Ser-
CC       657 (hydrophobic region), need to be phosphorylated for its full
CC       activation.
CC   -!- SUBUNIT: Recruited in a circadian manner into a nuclear complex which
CC       also includes BMAL1 and RACK1 (By similarity). Interacts with
CC       ADAP1/CENTA1 (PubMed:12893243). Interacts with CSPG4 (PubMed:15504744).
CC       Binds to CAVIN2 in the presence of phosphatidylserine (By similarity).
CC       Interacts with PRKCABP/PICK1 (via PDZ domain) (PubMed:15247289).
CC       Interacts with TRIM41 (PubMed:17893151). Interacts with PARD3
CC       (PubMed:27925688). Interacts with SOCS2 (By similarity).
CC       {ECO:0000250|UniProtKB:P05696, ECO:0000250|UniProtKB:P20444,
CC       ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:15247289,
CC       ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:17893151,
CC       ECO:0000269|PubMed:27925688}.
CC   -!- INTERACTION:
CC       P17252; Q15027: ACAP1; NbExp=3; IntAct=EBI-1383528, EBI-751746;
CC       P17252; Q06481-5: APLP2; NbExp=3; IntAct=EBI-1383528, EBI-25646567;
CC       P17252; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-1383528, EBI-5280499;
CC       P17252; Q13072: BAGE; NbExp=3; IntAct=EBI-1383528, EBI-25884811;
CC       P17252; Q8N9N5-2: BANP; NbExp=3; IntAct=EBI-1383528, EBI-11524452;
CC       P17252; Q96A33: CCDC47; NbExp=3; IntAct=EBI-1383528, EBI-720151;
CC       P17252; Q96LY2-2: CCDC74B; NbExp=3; IntAct=EBI-1383528, EBI-17967022;
CC       P17252; P15169: CPN1; NbExp=3; IntAct=EBI-1383528, EBI-2116369;
CC       P17252; P43234: CTSO; NbExp=3; IntAct=EBI-1383528, EBI-2874283;
CC       P17252; O95424: DEXI; NbExp=3; IntAct=EBI-1383528, EBI-724515;
CC       P17252; O43598: DNPH1; NbExp=3; IntAct=EBI-1383528, EBI-748674;
CC       P17252; P21728: DRD1; NbExp=3; IntAct=EBI-1383528, EBI-6624459;
CC       P17252; P00533: EGFR; NbExp=3; IntAct=EBI-1383528, EBI-297353;
CC       P17252; P60228: EIF3E; NbExp=3; IntAct=EBI-1383528, EBI-347740;
CC       P17252; Q96J88-3: EPSTI1; NbExp=3; IntAct=EBI-1383528, EBI-25885343;
CC       P17252; Q8IVH2-2: FOXP4; NbExp=3; IntAct=EBI-1383528, EBI-25885364;
CC       P17252; Q96NE9-2: FRMD6; NbExp=3; IntAct=EBI-1383528, EBI-13213391;
CC       P17252; O14926: FSCN2; NbExp=3; IntAct=EBI-1383528, EBI-21017948;
CC       P17252; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-1383528, EBI-9088619;
CC       P17252; P19440-3: GGT1; NbExp=3; IntAct=EBI-1383528, EBI-21558069;
CC       P17252; Q9UJ42: GPR160; NbExp=3; IntAct=EBI-1383528, EBI-25885139;
CC       P17252; P62805: H4C9; NbExp=3; IntAct=EBI-1383528, EBI-302023;
CC       P17252; Q9UBN7: HDAC6; NbExp=2; IntAct=EBI-1383528, EBI-301697;
CC       P17252; P52597: HNRNPF; NbExp=3; IntAct=EBI-1383528, EBI-352986;
CC       P17252; Q92826: HOXB13; NbExp=3; IntAct=EBI-1383528, EBI-11317274;
CC       P17252; Q02363: ID2; NbExp=3; IntAct=EBI-1383528, EBI-713450;
CC       P17252; Q96FT9-2: IFT43; NbExp=3; IntAct=EBI-1383528, EBI-11944538;
CC       P17252; P17936: IGFBP3; NbExp=3; IntAct=EBI-1383528, EBI-715709;
CC       P17252; P26951: IL3RA; NbExp=3; IntAct=EBI-1383528, EBI-1757512;
CC       P17252; Q9BYR8: KRTAP3-1; NbExp=3; IntAct=EBI-1383528, EBI-9996449;
CC       P17252; Q9Y234: LIPT1; NbExp=3; IntAct=EBI-1383528, EBI-727376;
CC       P17252; P51884: LUM; NbExp=3; IntAct=EBI-1383528, EBI-725780;
CC       P17252; Q9H213: MAGEH1; NbExp=3; IntAct=EBI-1383528, EBI-473834;
CC       P17252; P80192: MAP3K9; NbExp=3; IntAct=EBI-1383528, EBI-3951604;
CC       P17252; Q15759: MAPK11; NbExp=3; IntAct=EBI-1383528, EBI-298304;
CC       P17252; A0JLT2-2: MED19; NbExp=3; IntAct=EBI-1383528, EBI-13288755;
CC       P17252; Q9H8H3: METTL7A; NbExp=3; IntAct=EBI-1383528, EBI-1390168;
CC       P17252; Q8N983-3: MRPL43; NbExp=3; IntAct=EBI-1383528, EBI-11109389;
CC       P17252; P49821: NDUFV1; NbExp=3; IntAct=EBI-1383528, EBI-748312;
CC       P17252; Q2M1J6: OXA1L; NbExp=3; IntAct=EBI-1383528, EBI-9978021;
CC       P17252; Q9BRX2: PELO; NbExp=3; IntAct=EBI-1383528, EBI-1043580;
CC       P17252; Q9Y6X2: PIAS3; NbExp=3; IntAct=EBI-1383528, EBI-2803703;
CC       P17252; P11309-2: PIM1; NbExp=2; IntAct=EBI-1383528, EBI-1018633;
CC       P17252; Q6P1J6-2: PLB1; NbExp=3; IntAct=EBI-1383528, EBI-10694821;
CC       P17252; Q9UNA4: POLI; NbExp=3; IntAct=EBI-1383528, EBI-741774;
CC       P17252; Q02156: PRKCE; NbExp=2; IntAct=EBI-1383528, EBI-706254;
CC       P17252; P07225: PROS1; NbExp=3; IntAct=EBI-1383528, EBI-2803380;
CC       P17252; Q3YEC7-3: RABL6; NbExp=3; IntAct=EBI-1383528, EBI-25885259;
CC       P17252; O94844: RHOBTB1; NbExp=3; IntAct=EBI-1383528, EBI-6426999;
CC       P17252; Q9NWS8-3: RMND1; NbExp=3; IntAct=EBI-1383528, EBI-25884400;
CC       P17252; Q9ULK6-3: RNF150; NbExp=3; IntAct=EBI-1383528, EBI-23640835;
CC       P17252; P18077: RPL35A; NbExp=3; IntAct=EBI-1383528, EBI-353383;
CC       P17252; P31431: SDC4; NbExp=2; IntAct=EBI-1383528, EBI-3913237;
CC       P17252; Q99643: SDHC; NbExp=3; IntAct=EBI-1383528, EBI-1224539;
CC       P17252; Q14141: SEPTIN6; NbExp=3; IntAct=EBI-1383528, EBI-745901;
CC       P17252; Q01105-2: SET; NbExp=3; IntAct=EBI-1383528, EBI-7481343;
CC       P17252; P37840: SNCA; NbExp=3; IntAct=EBI-1383528, EBI-985879;
CC       P17252; Q9Y5X0: SNX10; NbExp=3; IntAct=EBI-1383528, EBI-10329478;
CC       P17252; P56693: SOX10; NbExp=3; IntAct=EBI-1383528, EBI-1167533;
CC       P17252; Q9BRW5: SP2; NbExp=3; IntAct=EBI-1383528, EBI-25868254;
CC       P17252; O43761: SYNGR3; NbExp=3; IntAct=EBI-1383528, EBI-11321949;
CC       P17252; P15884: TCF4; NbExp=3; IntAct=EBI-1383528, EBI-533224;
CC       P17252; Q3YBM2: TMEM176B; NbExp=3; IntAct=EBI-1383528, EBI-2821479;
CC       P17252; P0CG48: UBC; NbExp=2; IntAct=EBI-1383528, EBI-3390054;
CC       P17252; P13051-2: UNG; NbExp=3; IntAct=EBI-1383528, EBI-25834258;
CC       P17252; Q8NB14: USP38; NbExp=3; IntAct=EBI-1383528, EBI-2512509;
CC       P17252; O95498: VNN2; NbExp=3; IntAct=EBI-1383528, EBI-21494555;
CC       P17252; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-1383528, EBI-12040603;
CC       P17252; Q9BQ24: ZFYVE21; NbExp=3; IntAct=EBI-1383528, EBI-2849569;
CC       P17252; Q05CR2: ZNF248; NbExp=3; IntAct=EBI-1383528, EBI-25835471;
CC       P17252; Q8N0Y2-2: ZNF444; NbExp=3; IntAct=EBI-1383528, EBI-12010736;
CC       P17252; O15535: ZSCAN9; NbExp=3; IntAct=EBI-1383528, EBI-751531;
CC       P17252; Q24008: inaD; Xeno; NbExp=2; IntAct=EBI-1383528, EBI-195326;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:23990668}. Cell
CC       membrane {ECO:0000269|PubMed:23990668}; Peripheral membrane protein
CC       {ECO:0000305|PubMed:23990668}. Mitochondrion membrane
CC       {ECO:0000269|PubMed:9738012}; Peripheral membrane protein
CC       {ECO:0000305|PubMed:9738012}. Nucleus {ECO:0000250|UniProtKB:P20444}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52479; CAA36718.1; -; mRNA.
DR   EMBL; AB451258; BAG70072.1; -; mRNA.
DR   EMBL; AB451383; BAG70197.1; -; mRNA.
DR   EMBL; AC005918; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005988; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006263; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006947; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC009452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC060796; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89014.1; -; Genomic_DNA.
DR   EMBL; BC109273; AAI09274.1; -; mRNA.
DR   EMBL; BC109274; AAI09275.1; -; mRNA.
DR   EMBL; M22199; AAA60098.1; -; mRNA.
DR   EMBL; AF395829; AAK84184.1; -; Genomic_DNA.
DR   CCDS; CCDS11664.1; -.
DR   PIR; S09496; KIHUCA.
DR   RefSeq; NP_002728.1; NM_002737.2.
DR   PDB; 2ELI; NMR; -; A=93-169.
DR   PDB; 3IW4; X-ray; 2.80 A; A/B/C=320-672.
DR   PDB; 4DNL; X-ray; 1.90 A; A=155-293.
DR   PDB; 4RA4; X-ray; 2.63 A; A=318-672.
DR   PDBsum; 2ELI; -.
DR   PDBsum; 3IW4; -.
DR   PDBsum; 4DNL; -.
DR   PDBsum; 4RA4; -.
DR   AlphaFoldDB; P17252; -.
DR   BMRB; P17252; -.
DR   SMR; P17252; -.
DR   BioGRID; 111564; 290.
DR   CORUM; P17252; -.
DR   DIP; DIP-531N; -.
DR   IntAct; P17252; 133.
DR   MINT; P17252; -.
DR   STRING; 9606.ENSP00000408695; -.
DR   BindingDB; P17252; -.
DR   ChEMBL; CHEMBL299; -.
DR   DrugBank; DB14001; alpha-Tocopherol succinate.
DR   DrugBank; DB06451; Aprinocarsen.
DR   DrugBank; DB09096; Benzoyl peroxide.
DR   DrugBank; DB11752; Bryostatin 1.
DR   DrugBank; DB14002; D-alpha-Tocopherol acetate.
DR   DrugBank; DB08846; Ellagic acid.
DR   DrugBank; DB05013; Ingenol mebutate.
DR   DrugBank; DB06595; Midostaurin.
DR   DrugBank; DB06641; Perifosine.
DR   DrugBank; DB00144; Phosphatidyl serine.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00163; Vitamin E.
DR   DrugCentral; P17252; -.
DR   GuidetoPHARMACOLOGY; 1482; -.
DR   iPTMnet; P17252; -.
DR   MetOSite; P17252; -.
DR   PhosphoSitePlus; P17252; -.
DR   SwissPalm; P17252; -.
DR   BioMuta; PRKCA; -.
DR   DMDM; 317373571; -.
DR   CPTAC; CPTAC-1615; -.
DR   EPD; P17252; -.
DR   jPOST; P17252; -.
DR   MassIVE; P17252; -.
DR   MaxQB; P17252; -.
DR   PaxDb; P17252; -.
DR   PeptideAtlas; P17252; -.
DR   PRIDE; P17252; -.
DR   ProteomicsDB; 53464; -.
DR   Antibodypedia; 1464; 1241 antibodies from 46 providers.
DR   DNASU; 5578; -.
DR   Ensembl; ENST00000413366.8; ENSP00000408695.3; ENSG00000154229.12.
DR   GeneID; 5578; -.
DR   KEGG; hsa:5578; -.
DR   MANE-Select; ENST00000413366.8; ENSP00000408695.3; NM_002737.3; NP_002728.2.
DR   UCSC; uc002jfp.2; human.
DR   CTD; 5578; -.
DR   DisGeNET; 5578; -.
DR   GeneCards; PRKCA; -.
DR   HGNC; HGNC:9393; PRKCA.
DR   HPA; ENSG00000154229; Tissue enhanced (brain).
DR   MIM; 176960; gene.
DR   neXtProt; NX_P17252; -.
DR   OpenTargets; ENSG00000154229; -.
DR   PharmGKB; PA33759; -.
DR   VEuPathDB; HostDB:ENSG00000154229; -.
DR   eggNOG; KOG0696; Eukaryota.
DR   GeneTree; ENSGT00940000156104; -.
DR   HOGENOM; CLU_000288_54_2_1; -.
DR   InParanoid; P17252; -.
DR   OMA; EGEFYNI; -.
DR   OrthoDB; 614710at2759; -.
DR   PhylomeDB; P17252; -.
DR   TreeFam; TF351133; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   PathwayCommons; P17252; -.
DR   Reactome; R-HSA-111933; Calmodulin induced events.
DR   Reactome; R-HSA-114516; Disinhibition of SNARE formation.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-399997; Acetylcholine regulates insulin secretion.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-4419969; Depolymerisation of the Nuclear Lamina.
DR   Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA.
DR   Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-9010642; ROBO receptors bind AKAP5.
DR   SABIO-RK; P17252; -.
DR   SignaLink; P17252; -.
DR   SIGNOR; P17252; -.
DR   BioGRID-ORCS; 5578; 12 hits in 1109 CRISPR screens.
DR   ChiTaRS; PRKCA; human.
DR   EvolutionaryTrace; P17252; -.
DR   GeneWiki; PKC_alpha; -.
DR   GenomeRNAi; 5578; -.
DR   Pharos; P17252; Tchem.
DR   PRO; PR:P17252; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P17252; protein.
DR   Bgee; ENSG00000154229; Expressed in CA1 field of hippocampus and 190 other tissues.
DR   ExpressionAtlas; P17252; baseline and differential.
DR   Genevisible; P17252; HS.
DR   GO; GO:0035866; C:alphav-beta3 integrin-PKCalpha complex; ISS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; IEA:UniProtKB-EC.
DR   GO; GO:0019899; F:enzyme binding; IDA:BHF-UCL.
DR   GO; GO:0035403; F:histone kinase activity (H3-T6 specific); IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; ISS:BHF-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; EXP:Reactome.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0002159; P:desmosome assembly; IMP:BHF-UCL.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007077; P:mitotic nuclear membrane disassembly; TAS:Reactome.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:ARUK-UCL.
DR   GO; GO:0106071; P:positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT.
DR   GO; GO:0045780; P:positive regulation of bone resorption; ISS:BHF-UCL.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0043687; P:post-translational protein modification; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0090330; P:regulation of platelet aggregation; IDA:UniProtKB.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05615; STKc_cPKC_alpha; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR046349; C1-like_sf.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR034663; cPKC_alpha.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57889; SSF57889; 2.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding; Calcium;
KW   Cell adhesion; Cell membrane; Cytoplasm; Direct protein sequencing; Kinase;
KW   Membrane; Metal-binding; Mitochondrion; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Proto-oncogene; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0007744|PubMed:19413330, ECO:0007744|PubMed:22814378"
FT   CHAIN           2..672
FT                   /note="Protein kinase C alpha type"
FT                   /id="PRO_0000055679"
FT   DOMAIN          158..275
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          339..597
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          598..668
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ZN_FING         36..86
FT                   /note="Phorbol-ester/DAG-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ZN_FING         101..151
FT                   /note="Phorbol-ester/DAG-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00226"
FT   ACT_SITE        463
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         186
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         187
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         193
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         195
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         245
FT                   /ligand="a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
FT                   inositol-4,5-bisphosphate)"
FT                   /ligand_id="ChEBI:CHEBI:58456"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         246
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         247
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         248
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         252
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         254
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="3"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   BINDING         345..353
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         368
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330,
FT                   ECO:0007744|PubMed:22814378"
FT   MOD_RES         10
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         319
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05696"
FT   MOD_RES         494
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04409"
FT   MOD_RES         495
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P04409"
FT   MOD_RES         497
FT                   /note="Phosphothreonine; by PDPK1"
FT                   /evidence="ECO:0000250|UniProtKB:P04409, ECO:0000305"
FT   MOD_RES         501
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P05771"
FT   MOD_RES         628
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         631
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P68403, ECO:0000255"
FT   MOD_RES         638
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:24275569"
FT   MOD_RES         651
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         657
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         658
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:P20444"
FT   VARIANT         98
FT                   /note="P -> S (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042301"
FT   VARIANT         467
FT                   /note="D -> N (in a glioblastoma multiforme sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042302"
FT   VARIANT         489
FT                   /note="M -> V (in dbSNP:rs34406842)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042303"
FT   VARIANT         568
FT                   /note="V -> I (in dbSNP:rs6504459)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:19054851, ECO:0000269|PubMed:2336401,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_050558"
FT   CONFLICT        50
FT                   /note="C -> S (in Ref. 6; AAA60098)"
FT                   /evidence="ECO:0000305"
FT   TURN            98..100
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   STRAND          105..107
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   STRAND          116..118
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   STRAND          125..127
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   STRAND          129..131
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   STRAND          133..135
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   STRAND          138..140
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   TURN            141..146
FT                   /evidence="ECO:0007829|PDB:2ELI"
FT   STRAND          161..169
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   STRAND          172..182
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   STRAND          194..202
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   STRAND          222..230
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   HELIX           233..237
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   STRAND          239..246
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   STRAND          254..262
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   HELIX           263..268
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   STRAND          271..276
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   HELIX           282..284
FT                   /evidence="ECO:0007829|PDB:4DNL"
FT   HELIX           336..338
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          339..350
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          352..361
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          364..371
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           372..377
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           381..392
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          403..408
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          410..417
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          422..424
FT                   /evidence="ECO:0007829|PDB:3IW4"
FT   HELIX           425..432
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           437..456
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           466..468
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          469..471
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   STRAND          477..479
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           502..504
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           507..510
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           518..533
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           543..552
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           563..572
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           577..579
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           587..593
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           595..597
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           602..606
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           642..646
FT                   /evidence="ECO:0007829|PDB:4RA4"
FT   HELIX           650..653
FT                   /evidence="ECO:0007829|PDB:4RA4"
SQ   SEQUENCE   672 AA;  76750 MW;  9EB157789A062349 CRC64;
     MADVFPGNDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS
     LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVAD EKLHVTVRDA
     KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL
     SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNME
     LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG
     TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV
     NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA
     DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG
     EDEDELFQSI MEHNVSYPKS LSKEAVSVCK GLMTKHPAKR LGCGPEGERD VREHAFFRRI
     DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN
     PQFVHPILQS AV
//
